MIRA Secures Worldwide Exclusive Rights for MIRA-55 and SKNY-1 Programs
MIRA sits 16% above its 52-week low of $0.9.
Summary
MIRA Pharmaceuticals has obtained worldwide exclusive rights for its MIRA-55 and SKNY-1 drug programs, strengthening its intellectual property and global commercialization potential for key pipeline assets.
Key Events · M&A and Partnerships · MIRA
-
Worldwide Exclusive Rights Secured
MIRA Pharmaceuticals entered an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, granting worldwide exclusive rights for its MIRA-55 and SKNY-1 development programs.
-
Strengthens IP Portfolio
The agreement consolidates intellectual property and establishes a unified global rights structure across MIRA's core therapeutic assets, including Ketamir-2, MIRA-55, and SKNY-1.
-
No Material Change to Economic Terms
The amendment does not materially modify the previously disclosed core economic terms of the existing license arrangements.
-
Follows Prior IP Expansion
This follows a similar expansion of worldwide exclusive rights for the Ketamir-2 program announced on May 27, 2026, completing global control over the company's pipeline.
Analysis · MIRA · Life Sciences
This 8-K announces MIRA Pharmaceuticals has secured worldwide exclusive development and commercialization rights for its MIRA-55 and SKNY-1 drug candidates through an amended license agreement with MIRALOGX LLC. This move consolidates the company's intellectual property portfolio and establishes a unified global rights structure across its core therapeutic assets, including Ketamir-2, which previously secured worldwide rights. For a clinical-stage company with a "going concern" warning, securing global rights for its pipeline is crucial for attracting future partners and financing, which are essential for advancing drug development and commercialization.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.8% of the 1152 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.4M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.